In the second positive update on its small molecule programme this month (the earlier preclinical data on liver disease being flagged in our Research Note of 20 April), the biopharmaceutical Company focused on the biology of healing has this week provided strong positive confirmatory data from ProMetic’s expanded open label clinical trial studying type 2 diabetes and the metabolic syndrome. This gives us cause to be optimistic about the forthcoming programme of multiple placebo controll
28 Apr 2016
Yet more good clinical data on PBI-4050
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Yet more good clinical data on PBI-4050
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
28 Apr 2016 -
Author:
Derren Nathan -
Pages:
7
In the second positive update on its small molecule programme this month (the earlier preclinical data on liver disease being flagged in our Research Note of 20 April), the biopharmaceutical Company focused on the biology of healing has this week provided strong positive confirmatory data from ProMetic’s expanded open label clinical trial studying type 2 diabetes and the metabolic syndrome. This gives us cause to be optimistic about the forthcoming programme of multiple placebo controll